Cajal Neuroscience launches with $96 million to transform target and drug discovery in neurodegeneration
Cajal aims to accelerate drug discovery for neurodegeneration by enabling target discovery and validation at unprecedented scale The team combines expertise in neuroscience, computational biology, high-throughput functional genomics and advanced microscopy Funding led by The Column Group and Lux Capital SEATTLE, November 29, 2022–(BUSINESS WIRE)–Cajal Neuroscience, a biotechnology company integrating human genetics, functional genomics and …